Healthcare - Press Releases

-Intellisense AFib-Technologie erkennt bei jeder Messung mgliches Vorhofflimmern; der 17. Mai ist Welt-Blutdrucktag im, dem Monat der Blutdruckmessung -May Measurement Month -

OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month follow-up results from its Phase 1 clinical trial (RAD-18-001) evaluating Radspherin in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The trial was closed for recruitment at the end of 2023 and patients are currently in long-term follow-up.

OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update,Oncoinvent invites for a Live streamed of quarterly presentation in English on Wednesday 30thof April at 11.00 AM CEST. A webcast will be available for everyone to view on www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar.

SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stagein vivogene editing company committed to pioneering the next generation of precision genetic medicines, announced promising interim clinical data from an investigator-initiated trial (IIT) of YOLT-101 (NCT06458010), and the data has been published on medRxiv. YOLT-101 is an investigationalin vivobase editing therapy for the treatment of heterozygous familial hypercholesterolemia (HeFH). Clinical data demonstrate that YOLT-101 can safely and effectively reduce low-density lipoprotein cholesterol (LDL-C) levels in HeFH patients with a single administration. As a next-generation gene-editing therapy, YOLT-101 represents a breakthrough in lipid-lowering treatment - moving beyond daily pills and regular injections, and opening a new era of "one-time treatment for lifelong LDL-C reduction."

PAPHOS, Cyprus, April 28, 2025 /PRNewswire/ -- ILIKOS Consulting Group, a leader in commercial strategy, BD and corporate development solutions for Contract Research Organizations (CROs) and life-science companies proudly announces the launch of its new subsidiary in Greece. This strategic move underscores the company's commitment to expanding its international footprint and enhancing its portfolio of business solutions.

FUKUOKA, Japon, 28 avril 2025 /PRNewswire/ -- EditForce, Inc. (Sige social: Fukuoka, Japon) a le plaisir d'annoncer qu'un article de recherche sur les rsultats d'une tude conjointe avec le groupe de recherche dirig par le professeur Masayuki Nakamori du dpartement de neurologie de l'cole suprieure de mdecine de l'Universit de Yamaguchi, et le professeur Hideki Mochizuki du dpartement de neurologie de l'cole suprieure de mdecine de l'Universit d'Osaka, a t publi dans Science Translational Medicine le 16 avril 2025 (heure avance de l'Est).

STOCKHOLM, April 28, 2025 /PRNewswire/ -- Bioservo is excited to unveil the latest innovation in grip-strengthening technology, the New Carbonhand glove. This advanced glove features several enhancements and is designed to support different types of grips to make everyday tasks easier and more accessible. This also means that more people can benefit from Carbonhand.

LUXEMBURG, 24. April 2025 /PRNewswire/ -- Die Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), ein fhrender Innovator im Bereich Sport- und Gesundheitstechnologie, der fortschrittliche tragbare AIoT-Lsungen anbietet, die die berwachung der sportlichen Leistung nahtlos mit Echtzeit-Gesundheitsdaten verbinden, freut sich, Hubertus Bert" Hoyt als neuesten Berater des Vorstands bekannt zu geben.

LUXEMBOURG, April 23, 2025 /PRNewswire/ -- Decentralized Biotechnology Intelligence Holding Group Inc. (dBio), a leading innovator in sports and health tech, delivering advanced wearable AIoT solutions that seamlessly merge athletic performance monitoring with real-time health insights, is pleased to announce Hubertus "Bert" Hoyt as its newest Board Advisor.

- Un gran avance en la monitorizacin de la ciruga cerebral: Protegiendo vidas con la tecnologa de imagen trmica de Raytron

YANTAI, Chine, 24 avril 2025 /PRNewswire/ -- En neurochirurgie, il est essentiel, mais difficile, d'obtenir des informations en temps rel sur le dbit sanguin crbral. L'imagerie conventionnelle par fluorescence du vert d'indocyanine (ICG) repose sur des agents de contraste et offre une rptabilit limite. Aujourd'hui, les camras de thermographie infrarouge offrent une alternative d'imagerie diagnostique sans contact, sans contraste, sans rayonnement et non invasive, ce qui permet une surveillance continue pour amliorer la prcision chirurgicale et la scurit des patients.

SHANGHAI and HONG KONG, April 23, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will release the latest clinical data of the CD73 small molecule inhibitor ATG-037 and the mTORC1/2 small molecule inhibitor ATG-008 in Poster Presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30th to June 3rd in Chicago, IL, the United States.

CHENGDU, China, April 24, 2025 /PRNewswire/ -- SichuanKelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30 to June 3. Results include data from its TROP2 antibody-drug conjugate (ADC)sacituzumab tirumotecan(sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be published on the ASCO's official website on May 22, 2025, local time.

Solid performance with higher sales and strong cash flow

Solid performance with higher sales and strong cash flow

SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com.

GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ --

Strong product sales and key progress in pipeline catalysts

Strong product sales and key progress in pipeline catalysts

- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles -

YANTAI, China, 24. April 2025 /PRNewswire/ -- In der Neurochirurgie mit hohem Einsatzist die Gewinnung von Echtzeit-Einblicken in den zerebralen Blutfluss lebenswichtig, aber auch eine Herausforderung. Die herkmmliche Indocyaningrn (ICG)-Fluoreszenzbildgebung ist auf Kontrastmittel angewiesen und bietet nur eine begrenzte Wiederholbarkeit. Jetzt versprechen Infrarot-Thermografiekameras eine berhrungslose, kontrastfreie, strahlungsfreie und nicht-invasive Alternative zur diagnostischen Bildgebung, die eine kontinuierliche berwachung ermglicht und die chirurgische Przision und Patientensicherheit erhht.

-Intellisense AFib Technology Able to Detect Possible Atrial Fibrillation with Every Measurement; May 17 Marks World Hypertension Day during May Measurement Month -

-Intellisense AFib Technology Able to Detect Possible Atrial Fibrillation with Every Measurement; May 17 Marks World Hypertension Day during May Measurement Month -

GOSSELIES, Belgium and NANTES, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in autoimmune and inflammatory disease drug development. The SAB will work closely with the AbolerIS team to advance its lead program, ABO21009, a humanized anti-CD45RC monoclonal antibody, through Phase 1 for rheumatoid arthritis (RA). Pending clinical proof-of-concept in RA, the Company intends to broaden its development into other autoimmune diseases. Durable, long-term remission remains elusive in many autoimmune diseases such as RA. The SAB will also assist the AbolerIS management with the planned development of additional indications for ABO21009 and the expansion and subsequent development of the Company's portfolio.

LOS ALTOS, Calif., April 24, 2025 /PRNewswire/ -- XYRA LLC, a private biopharmaceutical company, is committed to developing innovative therapies for cardiac rhythm disorders with high unmet need. With widespread use of FDA approved wearable Atrial Fibrillation (AF) monitoring devices in detecting as well as monitoring arrhythmias, it is now possible to identify subjects with long episodes of AF (LEAF) and symptoms who are at high risk of complications including stroke, heart failure and progression to permanent AF.